| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 |
| Sales | 3,000 | 2,500 | 0 | 4,930 | 4,090 |
| Sales Growth | +20.00% | unch | -100.00% | +20.54% | -15.32% |
| Net Income | -102,690 | -64,940 | -54,440 | -28,860 | -13,940 |
| Net Income Growth | -58.13% | -19.29% | -88.63% | -107.03% | -154.84% |
Ra Pharmaceuticals Inc (RARX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Fiscal Year End Date: 12/31